Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMY) Stock Analysis

$56.670

-0.895 (-1.58%)At close

Loading chart…
High
58.024
Open
57.775
VWAP
56.95
Volume
16.96M
Mkt Cap
84.14B
Low
56.150
Amount
965.80M
EV/EBITDA, TTM
7.55

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).

www.bms.com

AI analysis of Bristol-Myers Squibb Company (BMY)

Buy

Bristol-Myers Squibb is a good buy right now due to its current price of $59.12, which is below the analyst price target of $66 from BofA. Additionally, the company has a strong gross margin of 68.03% reported in Q2 2026, indicating solid profitability. However, the main risk is the declining revenue trend, with a slight decrease of 0.2% year-over-year reported for FY 2025.

Analyst Ratings (22)

-1.43% Downside
Hold
9 Buy
11 Hold
2 Sell
Current: 56.67
Low
37.00
Average
55.86
High
68.00

Jefferies

2026-10-12

Price Target

$76

Buy

William Blair

2026-10-12

Price Target

—

Market Perform

BofA

2026-10-09

Price Target

$66

Buy

Cantor Fitzgerald

2026-10-08

Price Target

$53

Neutral

Morgan Stanley

2026-10-07

Price Target

$41

Underweight

Valuation Metrics

The current forward P/E ratio for Bristol-Myers Squibb Company (BMY) is 9.36, compared to its 5-year average forward P/E of 11.38.

Forward P/E

Fair
5Y Average P/E
11.38
Current P/E
9.36
Overvalued
24.94
Undervalued
-2.19

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
10.20
Current EV/EBITDA
7.55
Overvalued
14.39
Undervalued
6.01

Forward P/S

Fair
5Y Average P/S
2.67
Current P/S
2.38
Overvalued
3.19
Undervalued
2.16

Alphio AI Price Scenarios for BMY

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%BMY

$44.66

Scenario price

B

Base

Base · 50%BMY

$40.66

Scenario price

B

Bear

Bear · 25%BMY

$35.77

Scenario price

Whales holding BMY

T

Turtle Creek Management, LLC

+ HoldingBMY

+22.84%

3M Return

C

Cbus Industry Superannuation Fund

+ HoldingBMY

+9.46%

3M Return

D

DWS Investment Management Americas, Inc.

+ HoldingBMY

+9.29%

3M Return

N

Nan Shan Life Insurance Co., Ltd.

+ HoldingBMY

+8.09%

3M Return

V

Van Eck Associates Corporation

+ HoldingBMY

+7.92%

3M Return

S

Sofinnova Investments, Inc.

+ HoldingBMY

+7.70%

3M Return

Events Timeline

2026-10-12 (ET)

14:00:00

RBC Analyst Calls Bristol Myers Drug Results Positive

09:00:00

S&P 500 Futures Mixed as Oil Prices Rise

07:00:00

Bristol Myers Squibb Announces Positive ACTION-1 Trial Results

07:00:00

Bristol Myers Squibb Announces Phase 3 Trial Results for Admilparant

2026-10-08 (ET)

07:30:00

Bristol Myers Announces Positive Phase 3 Results for Zenbexus

News

BMY FAQ — answered by Alphio AI

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Bristol-Myers Squibb is a good buy right now due to its current price of $59.12, which is below the analyst price target of $66 from BofA. Additionally, the company has a strong gross margin of 68.03% reported in Q2 2026, indicating solid profitability. However, the main risk is the declining revenue trend, with a slight decrease of 0.2% year-over-year reported for FY 2025.

22 analysts cover BMY: 9 rate it Buy, 11 Hold and 2 Sell. The average price target is 55.86.

Community

More ↗
molten_vortex9/26/2026

Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT

Show more
RektEddy9/15/2026

$PGR $SYK $BMY Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.

Show more
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started